{"classes":[{"categories":[{"measurements":[{"comment":"Median and upper end of the confidence interval cannot be estimated because duration of response was censored at the time of data cut off in 6/9 responders since these 6 participants have not had disease recurrence and therefore did not have a duration of response. The other 20 participants on this cohort were not assessed for duration of response as they did not have a response to begin with. Therefore median duration of response and upper end of the confidence interval cannot be calculated.","groupId":"OG000","lowerLimit":"8.3","upperLimit":"NA","value":"NA"},{"comment":"The upper end of the confidence interval cannot be estimated because of the low number of responding participants (n=2) assessed for duration of response in this cohort. In addition, the other 24 participants on this cohort were not assessed for duration of response as they did not have a response to begin with. Therefore the upper end of the confidence interval cannot be calculated.","groupId":"OG001","lowerLimit":"2.8","upperLimit":"NA","value":"4.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"2"}],"units":"Participants"}],"description":"Duration of response is defined as the time from complete response or partial response (whichever is first recorded) until the first date that recurrent or progressive disease (PD) is objectively documented. Response was measured by the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Complete response is disappearance of all target lesions. Partial response is at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progression is at least a 20% increase in the sum of diameters of target lesions, or appearance of one or more new lesions.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with anal cancer, non-neuroendocrine cervical cancer, P16 positive (P16+) oropharyngeal cancers, and other rare HPV associated tumors (e.g., squamous cell rectal, vulvar, vaginal, penile cancer, neuroendocrine cervical) naïve to checkpoint inhibition treated with M7824 at a flat dose of 1,200 mg intravenous (IV) once every 2 weeks until confirmed progressive disease, death, unacceptable toxicity, or study withdrawal.","id":"OG000","title":"Participants Naïve to Checkpoint Inhibition - M7824 1,200 mg Intravenous Once Every 2 Weeks"},{"description":"Participants with human papillomavirus (HPV) associated cancers refractory to checkpoint inhibition treated with M7824 at a flat dose of 1,200 mg intravenous (IV) once every 2 weeks until confirmed progressive disease, death, unacceptable toxicity, or study withdrawal.","id":"OG001","title":"Participants Refractory to Checkpoint Inhibition - M7824 1,200 mg Intravenous Once Every 2 Weeks"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Time from complete response or partial response (whichever is first recorded) until the first date that recurrent or progressive disease (PD) is objectively documented, up to 12 months","title":"Duration of Response (Complete Response or Partial Response)","type":"SECONDARY","unitOfMeasure":"Months"}